Cargando…

TNFAIP8 Promotes Cisplatin Chemoresistance in Triple-Negative Breast Cancer by Repressing p53-Mediated miR-205-5p Expression

Tumor necrosis factor alpha-induced protein 8 (TNFAIP8) is implicated in the tumor progression and prognosis of triple-negative breast cancer (TNBC), but the detailed regulatory mechanism of TNFAIP8 in cisplatin tolerance in TNBC has not yet been investigated. TNFAIP8 was evidently upregulated in TN...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Hong-Yu, Li, Yang, Yin, Hui-Zi, Yin, Hang, Qu, Yuan-Yuan, Xu, Qing-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581818/
https://www.ncbi.nlm.nih.gov/pubmed/33230463
http://dx.doi.org/10.1016/j.omtn.2020.09.025
_version_ 1783599055119581184
author Ma, Hong-Yu
Li, Yang
Yin, Hui-Zi
Yin, Hang
Qu, Yuan-Yuan
Xu, Qing-Yong
author_facet Ma, Hong-Yu
Li, Yang
Yin, Hui-Zi
Yin, Hang
Qu, Yuan-Yuan
Xu, Qing-Yong
author_sort Ma, Hong-Yu
collection PubMed
description Tumor necrosis factor alpha-induced protein 8 (TNFAIP8) is implicated in the tumor progression and prognosis of triple-negative breast cancer (TNBC), but the detailed regulatory mechanism of TNFAIP8 in cisplatin tolerance in TNBC has not yet been investigated. TNFAIP8 was evidently upregulated in TNBC tumor tissues and cell lines. Knocking down TNFAIP8 led to impaired proliferation and elevated apoptosis of TNBC cells upon cisplatin (DDP) treatment. Mechanistic studies revealed that TNFAIP8 repressed the expression of p53 and p53-promoted microRNA (miR)-205-5p; moreover, miR-205-5p targeted multiple genes required for the cell cycle and repressed Akt phosphorylation, which thus inhibited the proliferation of TNBC cells. In addition, silencing of TNFAIP8 led to the upregulation of miR-205-5p and the restraint of the TRAF2-NF-κB pathway, which thus enhanced the suppressive effects of DDP on tumor growth in nude mice. This study revealed that TNFAIP8 was essential in the DDP tolerance formation of TNBC cells by reducing p53-promoted miR-205-5p expression. Thus, targeting TNFAIP8 might become a promising strategy to suppress TNBC progression.
format Online
Article
Text
id pubmed-7581818
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-75818182020-11-02 TNFAIP8 Promotes Cisplatin Chemoresistance in Triple-Negative Breast Cancer by Repressing p53-Mediated miR-205-5p Expression Ma, Hong-Yu Li, Yang Yin, Hui-Zi Yin, Hang Qu, Yuan-Yuan Xu, Qing-Yong Mol Ther Nucleic Acids Original Article Tumor necrosis factor alpha-induced protein 8 (TNFAIP8) is implicated in the tumor progression and prognosis of triple-negative breast cancer (TNBC), but the detailed regulatory mechanism of TNFAIP8 in cisplatin tolerance in TNBC has not yet been investigated. TNFAIP8 was evidently upregulated in TNBC tumor tissues and cell lines. Knocking down TNFAIP8 led to impaired proliferation and elevated apoptosis of TNBC cells upon cisplatin (DDP) treatment. Mechanistic studies revealed that TNFAIP8 repressed the expression of p53 and p53-promoted microRNA (miR)-205-5p; moreover, miR-205-5p targeted multiple genes required for the cell cycle and repressed Akt phosphorylation, which thus inhibited the proliferation of TNBC cells. In addition, silencing of TNFAIP8 led to the upregulation of miR-205-5p and the restraint of the TRAF2-NF-κB pathway, which thus enhanced the suppressive effects of DDP on tumor growth in nude mice. This study revealed that TNFAIP8 was essential in the DDP tolerance formation of TNBC cells by reducing p53-promoted miR-205-5p expression. Thus, targeting TNFAIP8 might become a promising strategy to suppress TNBC progression. American Society of Gene & Cell Therapy 2020-09-26 /pmc/articles/PMC7581818/ /pubmed/33230463 http://dx.doi.org/10.1016/j.omtn.2020.09.025 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Ma, Hong-Yu
Li, Yang
Yin, Hui-Zi
Yin, Hang
Qu, Yuan-Yuan
Xu, Qing-Yong
TNFAIP8 Promotes Cisplatin Chemoresistance in Triple-Negative Breast Cancer by Repressing p53-Mediated miR-205-5p Expression
title TNFAIP8 Promotes Cisplatin Chemoresistance in Triple-Negative Breast Cancer by Repressing p53-Mediated miR-205-5p Expression
title_full TNFAIP8 Promotes Cisplatin Chemoresistance in Triple-Negative Breast Cancer by Repressing p53-Mediated miR-205-5p Expression
title_fullStr TNFAIP8 Promotes Cisplatin Chemoresistance in Triple-Negative Breast Cancer by Repressing p53-Mediated miR-205-5p Expression
title_full_unstemmed TNFAIP8 Promotes Cisplatin Chemoresistance in Triple-Negative Breast Cancer by Repressing p53-Mediated miR-205-5p Expression
title_short TNFAIP8 Promotes Cisplatin Chemoresistance in Triple-Negative Breast Cancer by Repressing p53-Mediated miR-205-5p Expression
title_sort tnfaip8 promotes cisplatin chemoresistance in triple-negative breast cancer by repressing p53-mediated mir-205-5p expression
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581818/
https://www.ncbi.nlm.nih.gov/pubmed/33230463
http://dx.doi.org/10.1016/j.omtn.2020.09.025
work_keys_str_mv AT mahongyu tnfaip8promotescisplatinchemoresistanceintriplenegativebreastcancerbyrepressingp53mediatedmir2055pexpression
AT liyang tnfaip8promotescisplatinchemoresistanceintriplenegativebreastcancerbyrepressingp53mediatedmir2055pexpression
AT yinhuizi tnfaip8promotescisplatinchemoresistanceintriplenegativebreastcancerbyrepressingp53mediatedmir2055pexpression
AT yinhang tnfaip8promotescisplatinchemoresistanceintriplenegativebreastcancerbyrepressingp53mediatedmir2055pexpression
AT quyuanyuan tnfaip8promotescisplatinchemoresistanceintriplenegativebreastcancerbyrepressingp53mediatedmir2055pexpression
AT xuqingyong tnfaip8promotescisplatinchemoresistanceintriplenegativebreastcancerbyrepressingp53mediatedmir2055pexpression